Evaluation of the Safety and Efficacy of Reformulated Raltegravir (MK-0518) 1200 mg Once Daily in Combination With TRUVADA™ in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-Naive Participants (MK-0518-292)

Inclusion Criteria:

- HIV-1 positive

- Naïve to antiretroviral therapy including investigational antiretroviral agents

- Not of reproductive potential or, if of reproductive potential agrees to 1) true
abstinence, or 2) use of an acceptable method of birth control during the study

Exclusion Criteria:

- Use of recreational or illicit drugs or has recent history of drug or alcohol abuse
or dependence

- Has been treated for a viral infection other than HIV-1 (such as hepatitis B) with an
agent that is active against HIV-1 including but not limited to adefovir, tenofovir,
entecavir, emtricitabine, or lamivudine

- Has documented or known resistance to raltegravir, emtricitabine, and/or tenofovir
before the first dose of study drug

- Has participated in a study with an investigational compound or device within 30 days
or anticipates participating in such a study during this study

- Has used systemic immunosuppressive therapy or immune modulators within 30 days or is
anticipated to need them during the study (short courses of corticosteroids are
allowed)

- Requires or is anticipated to require any of the following prohibited medications
while in the study: phenobarbital, phenytoin, rifampin, rifabutin, or calcium,
magnesium and aluminum containing antacids, such as TUMS™, Maalox™ and Milk of
Magnesia™

- Has significant hypersensitivity or other contraindication to any of the components
of the study drugs

- Has current, active diagnosis of acute hepatitis due to any cause

- Is pregnant, breastfeeding, or expecting to conceive during the study

- Female participant expecting to donate eggs or male participant expecting to donate
sperm during the study

- Is or has a family member (spouse or children) who is investigational staff or
sponsor staff directly involved in this trial